Skip to main content
Top
Published in: Breast Cancer Research 1/2022

Open Access 01-12-2022 | Breast Cancer | Research

Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?

Authors: Yanis Hassaine, Emmanuelle Jacquet, Arnaud Seigneurin, Patricia Delafosse

Published in: Breast Cancer Research | Issue 1/2022

Login to get access

Abstract

Background

The worldwide incidence of invasive breast cancer in women is increasing according to several studies. This increase in incidence seems to be higher in young women (< 40 years). However, the reasons for this trend are poorly understood. This article aims to provide the most recent estimates of this trend and assess whether there is indeed an increase in the incidence of breast cancer among young women to strengthen prevention campaigns.

Methods

We collected data from the Isere cancer registry in France of all invasive breast cancers from January 1990 to December 2018. The standardized incidence rate was calculated for four age groups (< 40 years, 40–49 years, 50–74 years, ≥ 75 years) for this period. The 10-year relative survival was evaluated for each age group age for two periods (1990–1999 and 2000–2008). From 2011 to 2013, we analyzed the incidence and 5-year relative survival by tumor subtype (triple negative, luminal, HER2 amplified) for each age group.

Results

A total of 23,703 cases were selected, including 1343 young women (< 40 years). The incidence of invasive breast cancer increased annually by 0,8% (95% CI 0,7; 1) in all age groups combined from 1990 to 2018. The highest incidence increase is found among young women, by 2,1% annually (95% CI 1,3; 2,8). Regarding tumor subtypes from 2011 to 2018, the incidence of triple negatives increases higher in young women (+ 1,4% by year, 95% CI − 8,2; 11) and those over 75 years (+ 4% by year, 95% CI − 5,1; 13,2), but the results are not statistically significant. 10-year relative survival in young women increased from 74,6% (95% CI 69,6; 78,9) to 78,3%(95% CI 73,7; 82,1) between 1990–1999 and 2000–2008, respectively. Five-year relative survival is better in young women among triple negative and HER2 amplified.

Conclusion

Our study confirms the current trend of increasing the incidence of breast cancer in young women, associated with improved survival very likely attributable to earlier diagnosis due to increased awareness, and improvements in treatment. A better individualized risk-based screening strategy is needed for these patients. Additional studies will be needed to more accurately assess the risk of developing breast cancer and improve diagnostic performance.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin mai. 2021;71(3):209–49.CrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin mai. 2021;71(3):209–49.CrossRef
2.
go back to reference Ahmad A. Breast cancer statistics: recent trends. Adv Exp Med Biol. 2019;1152:1–7.CrossRef Ahmad A. Breast cancer statistics: recent trends. Adv Exp Med Biol. 2019;1152:1–7.CrossRef
3.
go back to reference Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health août. 2020;8(8):e1027–37.CrossRef Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health août. 2020;8(8):e1027–37.CrossRef
4.
go back to reference Cowppli-Bony A, Colonna M, Ligier K, Jooste V, Defossez G, Monnereau A, et al. Descriptive epidemiology of cancer in metropolitan France: incidence, survival and prevalence. Bull Cancer août. 2019;106(7–8):617–34.CrossRef Cowppli-Bony A, Colonna M, Ligier K, Jooste V, Defossez G, Monnereau A, et al. Descriptive epidemiology of cancer in metropolitan France: incidence, survival and prevalence. Bull Cancer août. 2019;106(7–8):617–34.CrossRef
7.
go back to reference Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. JNCI J Natl Cancer Inst. 2007;99(15):1152–61.CrossRef Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. JNCI J Natl Cancer Inst. 2007;99(15):1152–61.CrossRef
9.
go back to reference Leclère B, Molinié F, Trétarre B, Stracci F, Daubisse-Marliac L, Colonna M, et al. Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study. Cancer Epidemiol. 2013;37(5):544–9.CrossRef Leclère B, Molinié F, Trétarre B, Stracci F, Daubisse-Marliac L, Colonna M, et al. Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study. Cancer Epidemiol. 2013;37(5):544–9.CrossRef
10.
go back to reference Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, et al. ESO–ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol. 2020;31(6):674–96.CrossRef Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, et al. ESO–ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol. 2020;31(6):674–96.CrossRef
11.
go back to reference Lanta Q, Arveux P, Asselain B. Epidemiology and socio-cultural specificities of young women with breast cancer. Bull Cancer. 2019;106(12S1):S4.CrossRef Lanta Q, Arveux P, Asselain B. Epidemiology and socio-cultural specificities of young women with breast cancer. Bull Cancer. 2019;106(12S1):S4.CrossRef
12.
go back to reference Daly AA, Rolph R, Cutress RI, Copson ER. A review of modifiable risk factors in young women for the prevention of breast cancer. Breast Cancer. 2021;13:241–57. Daly AA, Rolph R, Cutress RI, Copson ER. A review of modifiable risk factors in young women for the prevention of breast cancer. Breast Cancer. 2021;13:241–57.
13.
go back to reference Sancho-Garnier H, Colonna M. Breast cancer epidemiology. Presse Med. 2019;48(10):1076–84.CrossRef Sancho-Garnier H, Colonna M. Breast cancer epidemiology. Presse Med. 2019;48(10):1076–84.CrossRef
14.
go back to reference Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30.CrossRef Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30.CrossRef
15.
go back to reference Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE. 2009;4(11):e7695.CrossRef Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE. 2009;4(11):e7695.CrossRef
16.
go back to reference Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90.CrossRef Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90.CrossRef
17.
go back to reference Colonna M, Delafosse P, Uhry Z, Poncet F, Arveux P, Molinie F, et al. Is breast cancer incidence increasing among young women? An analysis of the trend in France for the period 1983–2002. Breast Juin. 2008;17(3):289–92.CrossRef Colonna M, Delafosse P, Uhry Z, Poncet F, Arveux P, Molinie F, et al. Is breast cancer incidence increasing among young women? An analysis of the trend in France for the period 1983–2002. Breast Juin. 2008;17(3):289–92.CrossRef
18.
go back to reference Guo F, Kuo Y, et al. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 2018;124(17):3500–9.CrossRef Guo F, Kuo Y, et al. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 2018;124(17):3500–9.CrossRef
20.
go back to reference Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011;306(17):1884–90.CrossRef Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011;306(17):1884–90.CrossRef
21.
go back to reference Jung S, Wang M, Anderson K, Baglietto L, Bergkvist L, Bernstein L, et al. Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. Int J Epidemiol Juin. 2016;45(3):916–28.CrossRef Jung S, Wang M, Anderson K, Baglietto L, Bergkvist L, Bernstein L, et al. Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. Int J Epidemiol Juin. 2016;45(3):916–28.CrossRef
22.
go back to reference Macacu A, Autier P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015;154(2):213–24.CrossRef Macacu A, Autier P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015;154(2):213–24.CrossRef
23.
go back to reference Dossus L, Boutron-Ruault MC, Kaaks R, Gram IT, Vilier A, Fervers B, et al. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer. 2014;134(8):1871–88.CrossRef Dossus L, Boutron-Ruault MC, Kaaks R, Gram IT, Vilier A, Fervers B, et al. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer. 2014;134(8):1871–88.CrossRef
24.
go back to reference Andler R, Guignard R, Spilka S, Le Nézet O, Pasquereau A, Richard JB, et al. Smoking and vaping in France. Rev Mal Respir Juin. 2018;35(6):673–85.CrossRef Andler R, Guignard R, Spilka S, Le Nézet O, Pasquereau A, Richard JB, et al. Smoking and vaping in France. Rev Mal Respir Juin. 2018;35(6):673–85.CrossRef
25.
go back to reference Premenopausal Breast Cancer Collaborative Group, Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018;4(11):e181771.CrossRef Premenopausal Breast Cancer Collaborative Group, Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018;4(11):e181771.CrossRef
26.
go back to reference Hardefeldt PJ, Penninkilampi R, Edirimanne S, Eslick GD. Physical activity and weight loss reduce the risk of breast cancer: a meta-analysis of 139 prospective and retrospective studies. Clin Breast Cancer août. 2018;18(4):e601–12.CrossRef Hardefeldt PJ, Penninkilampi R, Edirimanne S, Eslick GD. Physical activity and weight loss reduce the risk of breast cancer: a meta-analysis of 139 prospective and retrospective studies. Clin Breast Cancer août. 2018;18(4):e601–12.CrossRef
27.
go back to reference Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–8.CrossRef Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–8.CrossRef
28.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71.CrossRef Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71.CrossRef
29.
go back to reference Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–92.CrossRef Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–92.CrossRef
30.
go back to reference Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol févr. 2018;19(2):169–80.CrossRef Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol févr. 2018;19(2):169–80.CrossRef
32.
go back to reference Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506.CrossRef Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506.CrossRef
33.
go back to reference Moretta J, Berthet P, Bonadona V, Caron O, Cohen-Haguenauer O, Colas C, et al. The French genetic and cancer consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition. Bull Cancer. 2018;105(10):907–17.CrossRef Moretta J, Berthet P, Bonadona V, Caron O, Cohen-Haguenauer O, Colas C, et al. The French genetic and cancer consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition. Bull Cancer. 2018;105(10):907–17.CrossRef
34.
go back to reference Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308–14.CrossRef Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308–14.CrossRef
36.
go back to reference Crocetti E, Roche L, Buzzoni C, di Costanzo F, Molinié F, Caldarella A, et al. Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S85-91.CrossRef Crocetti E, Roche L, Buzzoni C, di Costanzo F, Molinié F, Caldarella A, et al. Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S85-91.CrossRef
37.
go back to reference Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat févr. 2012;131(3):1061–6.CrossRef Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat févr. 2012;131(3):1061–6.CrossRef
38.
go back to reference Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in young women (<40 Years) compared with older women is attributed to poorer survival in early stage disease. J Am Coll Surg Mars. 2009;208(3):341–7.CrossRef Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in young women (<40 Years) compared with older women is attributed to poorer survival in early stage disease. J Am Coll Surg Mars. 2009;208(3):341–7.CrossRef
39.
go back to reference Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer. 2019;144(6):1251–61.CrossRef Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer. 2019;144(6):1251–61.CrossRef
40.
go back to reference Fredholm H, Magnusson K, Lindström LS, Garmo H, Fält SE, Lindman H, et al. Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat. 2016;160(1):131–43.CrossRef Fredholm H, Magnusson K, Lindström LS, Garmo H, Fält SE, Lindman H, et al. Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat. 2016;160(1):131–43.CrossRef
41.
go back to reference Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, et al. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Res Treat Août. 2015;152(3):667–73.CrossRef Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, et al. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Res Treat Août. 2015;152(3):667–73.CrossRef
42.
go back to reference Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (age < 40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast. 2021;61:77–83.CrossRef Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (age < 40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast. 2021;61:77–83.CrossRef
43.
go back to reference Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.CrossRef Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.CrossRef
44.
go back to reference Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053–65.CrossRef Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053–65.CrossRef
45.
go back to reference Bharat A, Aft RL, Gao F, Margenthaler JA. Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol. 2009;100(3):248–51.CrossRef Bharat A, Aft RL, Gao F, Margenthaler JA. Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol. 2009;100(3):248–51.CrossRef
46.
go back to reference Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, et al. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012;17(6):775–82.CrossRef Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, et al. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012;17(6):775–82.CrossRef
47.
go back to reference Smith IE, Fribbens C. Management of breast cancer in older and frail patients. Breast. 2015;24(Suppl 2):S159-162.CrossRef Smith IE, Fribbens C. Management of breast cancer in older and frail patients. Breast. 2015;24(Suppl 2):S159-162.CrossRef
48.
go back to reference Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast-cancer screening — viewpoint of the IARC working group. N Engl J Med. 2015;372(24):2353–8.CrossRef Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast-cancer screening — viewpoint of the IARC working group. N Engl J Med. 2015;372(24):2353–8.CrossRef
49.
go back to reference Duffy SW, Tabár L, Yen AMF, Dean PB, Smith RA, Jonsson H, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126(13):2971–9.CrossRef Duffy SW, Tabár L, Yen AMF, Dean PB, Smith RA, Jonsson H, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126(13):2971–9.CrossRef
50.
go back to reference Tabár L, Dean PB, Chen THH, Yen AMF, Chen SLS, Fann JCY, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125(4):515–23.CrossRef Tabár L, Dean PB, Chen THH, Yen AMF, Chen SLS, Fann JCY, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125(4):515–23.CrossRef
51.
go back to reference Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen. 2012;19(Suppl 1):57–66.CrossRef Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen. 2012;19(Suppl 1):57–66.CrossRef
52.
go back to reference Hauge IHR, Pedersen K, Olerud HM, Hole EO, Hofvind S. The risk of radiation-induced breast cancers due to biennial mammographic screening in women aged 50–69 years is minimal. Acta Radiol déc. 2014;55(10):1174–9.CrossRef Hauge IHR, Pedersen K, Olerud HM, Hole EO, Hofvind S. The risk of radiation-induced breast cancers due to biennial mammographic screening in women aged 50–69 years is minimal. Acta Radiol déc. 2014;55(10):1174–9.CrossRef
53.
go back to reference Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.CrossRef Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.CrossRef
54.
go back to reference Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology janv. 2011;258(1):98–105.CrossRef Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology janv. 2011;258(1):98–105.CrossRef
55.
go back to reference Yankaskas BC, Haneuse S, Kapp JM, Kerlikowske K, Geller B, Buist DSM. Performance of first mammography examination in women younger than 40 years. J Natl Cancer Inst. 2010;102(10):692–701.CrossRef Yankaskas BC, Haneuse S, Kapp JM, Kerlikowske K, Geller B, Buist DSM. Performance of first mammography examination in women younger than 40 years. J Natl Cancer Inst. 2010;102(10):692–701.CrossRef
56.
go back to reference Desreux JAC. Breast cancer screening in young women. Eur J Obstet Gynecol Reprod Biol. 2018;1(230):208–11.CrossRef Desreux JAC. Breast cancer screening in young women. Eur J Obstet Gynecol Reprod Biol. 2018;1(230):208–11.CrossRef
57.
go back to reference Hellquist BN, Duffy SW, Abdsaleh S, Björneld L, Bordás P, Tabár L, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2011;117(4):714–22.CrossRef Hellquist BN, Duffy SW, Abdsaleh S, Björneld L, Bordás P, Tabár L, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2011;117(4):714–22.CrossRef
58.
go back to reference Jonsson H, Bordás P, Wallin H, Nyström L, Lenner P. Service screening with mammography in Northern Sweden: effects on breast cancer mortality - an update. J Med Screen. 2007;14(2):87–93.CrossRef Jonsson H, Bordás P, Wallin H, Nyström L, Lenner P. Service screening with mammography in Northern Sweden: effects on breast cancer mortality - an update. J Med Screen. 2007;14(2):87–93.CrossRef
59.
go back to reference Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih YCT, et al. Breast cancer screening for women at average risk: 2015 guideline update from the american cancer society. JAMA. 2015;314(15):1599–614.CrossRef Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih YCT, et al. Breast cancer screening for women at average risk: 2015 guideline update from the american cancer society. JAMA. 2015;314(15):1599–614.CrossRef
Metadata
Title
Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?
Authors
Yanis Hassaine
Emmanuelle Jacquet
Arnaud Seigneurin
Patricia Delafosse
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2022
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-022-01581-5

Other articles of this Issue 1/2022

Breast Cancer Research 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine